anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In clinical practice, the d-dimer levels rule out venous thromboembolism and diagnose disseminated intravascular coagulation. d-dimers increase in both physiological and pathological conditions. Liver cirrhosis, especially in the final stages, is characterized by complex coagulation and fibrinolysis factor disorders. Multiple mechanisms tried to explain the increased d-dimer levels in patients with liver cirrhosis and ascites. The d-dimer cut-off level used to rule out venous thromboembolism in cirrhosis is higher than that used to confirm the diagnosis of VTE or DIC in noncirrhotic patients. The cut-off d-dimer level used for the prognosis of thrombotic events is not standardized in advanced liver cirrhosis. Thus, it is necessary to update the clinical guidelines regarding the usefulness of d-dimer testing in advanced liver cirrhosis and the cut-off d-dimer levels, which should vary based on the detection method.
Ethacrynic acid is an unsaturated ketone derivative of an aryloxyacetic acid. It is designated chemically as [2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy] acetic acid, and has a molecular weight of 303.14. Ethacrynic acid is a white, or practically white, crystalline powder, very slightly soluble in water, but soluble in most organic solvents such as alcohols, chloroform, and benzene. Its molecular formula is C13H12Cl2O4 and its structural formula is:

Ethacrynate sodium, the sodium salt of ethacrynic acid, is soluble in water at 25°C to the extent of about 7 percent. Solutions of the sodium salt are relatively stable at about pH 7 at room temperature for short periods, but as the pH or temperature increases the solutions are less stable. The molecular weight of ethacrynate sodium is 325.12. Its molecular formula is C13H11Cl2NaO4 and its structural formula is:

Intravenous ethacrynate sodium for injection is a sterile freeze-dried powder and is supplied in a vial containing ethacrynate sodium equivalent to ethacrynic acid 50 mg. The inactive ingredient is mannitol, 62.5 mg.
The diagnosis of non-alcoholic steatohepatitis (NASH) still requires liver biopsy, an invasive procedure that can lead to complications. Impaired hepatic function, associated with chronic liver diseases, changes the metabolic pathways responsible for the biotransformation of certain volatile organic compounds (VOCs) exhaled in breath. Consequently, abundance of these VOCs on breath changes in the presence of chronic liver diseases and could be used as a non-invasive diagnostic tool. To date, identified VOCs with classification performance for chronic liver diseases are of exogenous origin and their abundance on breath is not only related to liver malfunction, but also to the extent of the everyday exposure to these compounds, mainly through dietary intake. To overcome this limitation, we established the exogenous volatile organic compound (EVOC) approach, based on the administration of a defined dose of a compound followed by its measurement on breath at different timepoints. We tested several compounds in healthy subjects and found that their levels on breath peak \~10 minutes after administration, followed by a progressive reduction. NASH-associated alterations of gene expression \[1\], and/or impaired hepatic function is expected to alter the reduction of administered compound on breath allowing for classification between NASH subjects and healthy controls. We plan to administer a cocktail of EVOCs made of limonene, benzyl alcohol, 2- pentanone, 2-butanol, and nonanal, compounds safe for human consumption, approved, and widely used in the European Union as food flavoring agents. The amounts we will administer are well below thresholds found to cause side effects in human or animal models. The working hypothesis is that NASH-induced changes of hepatic clearance of administered food flavors alters their amounts measured in breath allowing differentiation between NASH and healthy liver conditions. We aim to conduct a cross-sectional study with the objective to identify if changes in EVOCs metabolism have a diagnostic potential for subjects with advanced fibrosis.

Subjects with FibroScan-confirmed fibrosis are asked to fast overnight. Then they provide a baseline breath sample, followed by oral administration of the EVOCs cocktail, and sampling of additional breath samples at subsequent timepoints up to 90 minutes post ingestion
Treatment A (elinzanetant dose A). Treatment B (elinzanetant dose B). Treatment C (zopiclone 7.5 mg). Treatment D (placebo).
Tomato leaf curl New Delhi virus (ToLCNDV) is a begomovirus causing significant melon (Cucumis melo) crop losses globally. This study aims to map the ToLCNDV resistance in the PI 414723 melon accession, previously identified and characterized through phenotypic studies, thereby exploring shared genomic regions with the established resistant source WM-7. In the present study, WM-7 and PI 414723 were crossed with the susceptible accessions 'Rochet' and 'Blanco' respectively, to generate F1 hybrids. These hybrids were self-pollinated to generate the populations for mapping the ToLCNDV resistance region and designing markers for marker-assisted selection. Disease evaluation included visual symptom scoring, viral-load quantification and tissue printing. Genotyping-by-sequencing and SNP markers were used for quantitative trait loci (QTL) mapping. For genetic analysis, qPCR and bulked segregant RNA-seq (BSR-seq) were performed. Gene expression was assessed using RNA-seq, and qRT-PCR was used for confirmation. The research narrows the candidate region for resistance in WM-7 and identifies overlapping QTLs on chromosome 11 in PI 414723, found in the region of the DNA primase large subunit. BSR-seq and expression analyses highlight potential regulatory roles of chromosome 2 in conferring resistance. Differential expression was confirmed for six genes in the candidate region on chromosome 2. This study confirms the existence of common resistance genes in PI 414723 and WM-7.
This 12-week randomized-controlled clinical trial will be planned to conduct in a total of 120 male and female subjects from the Department of Psychiatry at Kaohsiung Chang Gung Memorial Hospital. Eligible subjects will be psychiatric patients, aged between 20-65 years old, who have psychiatric diagnosis of schizophrenia and fulfill the inclusion and exclusion criteria. The intervention with aerobic walking programs will be initiated after randomization for patients who continue their usual treatment. Subjects will be enrolled for 12 weeks aerobic walking treatment and randomly assigned to (1) treatment-as-usual, (2) treatment-as-usual plus aerobic walking. The wearable watch will be used during the participants join the walking programs. We will measure the treatment response to investigate the effect of aerobic walking in patients with schizophrenia. This study is being performed to investigate the possibly beneficial effects of aerobic walking on cognitive function in schizophrenia.
1439742 Nasal influenza vaccine RECHERCHE ET INDUSTRIE THERAPEUTIQUES 3 Feb 1975 [4 Feb 1974] 4535/75 Heading A5B A live influenza virus vaccine suitable for nasal administration comprises, as active ingredient an attenuated influenza type B virus strain recombinant obtained from (i) a vaccinal and attenuated influenza type B virus strain and (ii) another influenza type B virus strain, said recombinant having at least one marker property of said attenuated strain which is not shared by said other strain and the antigenic composition of said other strain. The attenuated strain may be Brigit strain. The recombinant may be influenza type BR5, R22 or R22 strain (ATCC VR787, 788 and 789 respectively). The recombinant may be prepared by combining the attenuated strain and the other strain in the allantoic cavity of embryonated chicken eggs, and isolating the recombinant by selective pressure. The isolate may be grown in the allantoic cavity of chicken eggs, admixed with a stabilizer, e.g. peptone or sugar, and freeze-dried. The vaccine may also include an attenuated influenza type A virus vaccine, e.g. Alice strain (ATCC VR776).
[GB1439742A]
The invention discloses an oligothiophene and a preparation method and application thereof. The oligothiophene provided by the invention has a structural formula shown as a formula (III), wherein an m equals to 3, and an n is an integer from 1-6. The oligothiophene can be applied to the following five aspects of: 1) preparation of cancer cell propagation inhibitor; 2) preparation of cancer cell apoptosis inducer; 3) preparation of treatments for preventing / or treating cancer; 4) preparation of mitochondrial targeting medicaments; 5) cell imaging as a mitochondrial dye. The oligothiophene of the invention reserves a skeleton of a conjugated polymer, so a fluorescent property of the conjugated polymer can be used for imaging. According to tests, the oligothiophene shown as the formula (III) is a specific dye for the mitochondrial. Besides, the oligothiophene shown as the formula (III) of the invention can be compounded with chlorambucil to form nano particles; and results show that the compound has wide-spectrum anticancer property, so as to increase anticancer activity.
A man in his 60s attended emergency for acute-onset abdominal pain and haematemesis. Requiring resuscitation, a CT abdomen/pelvis revealed a primary aortoenteric fistula actively bleeding into the duodenum. His background included a previous severe Q-fever infection and a heavy smoking history. Despite attempts at resuscitation and an emergent surgical attempt at haemostasis, the patient did not survive the massive gastrointestinal haemorrhage.Even in less severe cases, management of aortoenteric fistulas is tricky. Blood cultures and angiographic imaging are important investigations in guiding surgical approach. The pathology tends to have a significant rate of mortality even at tertiary-level vascular surgical centres.
Nitric oxide is a naturally occurring gas that plays a role in many body functions. Levels of eNO increase with airway inflammation, a symptom of asthma. Researchers have proposed using eNO as a noninvasive measure to guide physicians in the treatment and medical management of asthma in children. However, more information about eNO is needed before this can happen. This study will perform a secondary analysis of the results from its parent study, the CAP study, which evaluated the effectiveness of preventing asthma in children who had been exposed to environmental tobacco smoke.

This study will not enroll any new participants. Previously collected data from the CAP study will be reevaluated in this study to determine the longitudinal effects of environmental and genetic factors on eNO levels. In addition, the data will be evaluated to determine the relationship between eNO levels and asthma severity. No new data will be collected in this study.
Patients allocated to the intervention group will perform a single bout of supervised aerobic exercise. The starting time will be approximately 1630 hrs. The exercise mode will be a bicycle ergometer. After a warm-up period, during which the intensity is gradually increased, an intensity of 80% of the individual anaerobic threshold will be maintained for 30 minutes. The intensity level was chosen based on clinical experience that this corresponds to an approximate rate of perceived exertion of 13 (on a scale from 6-20) in this population.
NVX-CoV2373 (5 μg): Coformulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 μg antigen and 100 μg adjuvant per mL. The vaccination regimen will comprise of 1 intramuscular (IM) injection on Day 0 of 0.5 mL injection volume at a dose of 5 μg of antigen with 50 μg Matrix-M adjuvant.
GC chemotherapy every 3 weeks,with a total of 6 cycles. Lenvatinib 8 mg once daily (QD) oral dosing. Adebrelimab 1200mg intravenously every 3 weeks.
Parastomal hernia (PSH) is one of the most common stoma complications, with an incidence of 30-50 % within just a couple of years of stoma creation. Surgical parastomal hernia repair is a morbid and complicated procedure, with a 30-day reoperation rate of 13 % and 30-day mortality rate of 6 % in population-based surveys. There is no established gold standard diagnostic modality. Routinely, patients are examined clinically in various positions with and without increased intra-abdominal pressure. It has been shown in previous studies that clinical examination has a very low inter-observer reliability. Computerized tomography is often performed in addition to clinical examination, but is not ideal in diagnosing PSH either, not only beacause of insufficient test characteristics but also since the examinations should ideally be performed with specific protocols, prone position and be reviewed by a dedicated radiologist. The risk of incorrectly diagnosing a PSH (false positive) is that patients might subsequently be exposed to complex and dangerous surgical interventions without any health benefit, while incorrectly ruling out a PSH (false negative) can cause the patient to have to live with potentially treatable symptoms, life-threatening bowel incarceration being the most severe potential complication.

Thus, improved diagnostic accuracy is required. A method that has been developed within our research group is endostomal tree-dimensional ultrasonography, which has preliminarily proven to be approximately as sensitive as CT, with a markedly higher specificity. A larger and less selected study needs to be conducted in order to reliably calculate test characteristics, predictive values and likelihood ratio.
1292519 Granulated denture cleaning compositions COLGATE PALMOLIVE CO 13 April 1970 [14 April 1969] 17452/70 Heading C5D A powder composition for cleaning dentures is converted to granular form by (a) compressing and de-aerating it, (b) extruding it as a sheet, (c) breaking the sheet into granules and (d) separating granules of a particular size range from under- and over-sized material. In a particular embodiment, Fig. 1, the composition ingredients are introduced at hopper 12, mixed whilst being transported by screws 44 and 46 and conduit 20 to hopper 22 and transported by screw 24 to screw 26 which compresses and de-aerates them before expelling them through constructed outlet 52. The expelled material is rolled into a sheet which is broken up by rotating blades mounted on axle 30. Grid 32 retains the material in contact with the blades until it is fine enough to pass through to sorter 36, which screens out under- and oversized material for recycling via conduit 38 and discharges granules of the desired size at 42. In a second embodiment (Fig. 5, not shown), sheet extruded from the rollers is first broken into chips and flakes by an upper set of rotating blades (86) and then falls to a lower set (88) where it is granulated.
A multicenter, retrospective, observational trial will be conducted (APPLE study). To investigate whether a combined model constructed on the basis of pericoronary adipose tissue (PCAT) radiomics, fluid dynamics and clinical risk factors can predict the formation of atherosclerotic plaque. It will be carried out in 11 hospitals in 4 provinces in China. The Boruta algorithm and correlation proof clustering analysis were used to screen the imaging histological features, and a random forest model was used to construct an imaging histological prediction model for PCAT and fluid dynamics and to construct radiomics' score. To investigate the incremental value of the radiomics' score beyond the traditional prediction model, the radiomics' score was combined with the traditional logistic regression prediction model. Receiver operating characteristic (ROC) curve analysis with integrated discrimination improvement (IDI) and category net reclassification index (NRI) were used to compare the performance of the predictive models. A ML-prediction model incorporates FAI, fluid dynamics and patient clinical characteristics to identify high-risk patients in advance for patients receiving routine CCTA and guide the more precise use of preventative treatments, including anti-inflammatory therapies.
The invention belonging to the field of Chinese medicinal composition cosmetics provides a gelling agent for treating acne. The invention is characterized in that the gelling agent mainly comprises the following pharmaceutical components by the weight ratio: essential oil of mother chrysanthemum of 1-3, essential oil of honeysuckle flower of 1-3, essential oil of tree plant of 1-3, salicylic acid of 2, carbopol of 9405-15, alcohol of 30-80, intralipid of 30-80, polysorbate of 801-3, ethylparaben of 1-3, sodium hydroxide of 1-6, distilled water added to 1000. The invention has functions of heat clearing and detoxicating, carbuncle and swelling dispersing, treating of sores, carbuncles, furunculosis, whelk, adult acne and the like. The gelling agent which is transparent and beautiful has a large amount of water content and medicament content and a high transparent ratio, the gelling agent can make the medicament act continuously. The feeling of the gelling agent coated on skin is smooth, comfortable and non-fatness. The gelling agent has no effects on the normal physiological functions of skins.
This is a prospective study on 30 neonates with moderate to moderately to severe hypoxic ischemic encephalopathy (HIE) . HIE infants are randomized into two groups: Whole body cooling group (N = 15; receive 72 hours of whole body hypothermia) and melatonin/ hypothermia group (N = 15; receive hypothermia and 5 daily enteral doses of melatonin 10 mg/kg). Serum melatonin, plasma superoxide dismutase (SOD),and serum nitric oxide (NO) are measured at enrollment and after 2 weeks for the two HIE groups. The HIE groups underwent electroencephalography at enrollment and at 2 to 3 weeks. Brain MRI was performed after 2 weeks of life. Neurologic evaluations and Denver Developmental Screening Test II assessments were performed at 6 months. A group of healthy newborns will be used as a control for baseline labs.
Patients receive nivolumab IV over 30 minutes at week 0. Treatments repeat every 4 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients also receive radiation therapy on Monday-Friday or 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
The IBS-control group will not receive pain self-management intervention. Participants will be taught to use the abdominal belt/smart watch system for daily recording of bio-signals and voluntary report of episodes of visceral pain. We will follow up with all participants 4 weeks after enrollment, in a final lab visit, and measure primary outcomes to compare to the baseline data.
The invention discloses a preparation process and method of a traditional Chinese medicinal composition for treating acnes and spots. The traditional Chinese medicinal composition consists of the following raw materials: radix angelicae, radix scutellariae, coptis chinensis, cortex phellodendri, common hogfennei root, radix polygonati officinalis, radix clematidis, notopterygium root, radix paeoniae alba, salvia miltiorrhiza, coix seed, peppermint, liquorice root, white poria, honeysuckle, radix scutellariae, rheum officinale, radix sophorae flavescentis, radix ampelopsis, white atractylodes rhizome, white spirit and honey. The preparation method comprises the following steps: I. selecting raw materials; II. cleaning the raw materials; III. grinding and sieving the raw materials; IV. sealing and soaking; V. sieving for the second time and sealing; VI. preparing medicinal liquor; and VII. stirring, packaging and sealing. The traditional Chinese medicinal composition disclosed by the invention is prepared from traditional Chinese medicines, and the composition is quite excellent in effect on treating two symptoms, namely acnes and spots; and the composition is low in traditional Chinese medicine cost, so that people can afford the composition and effect is good.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to field of medicine, namely to surgery, traumatology, combustiology and dermatology and can be used for treatment and prevention of development of hypertrophic and keloidal scars. For this purpose lidase is introduced intradermally in therapeutic dose with its simultaneous transdermal introduction in average therapeutic dose. After that, after each procedure wet napkin, containing chitosan and collagenase with ratio 95:5, is applied on scar surface for 24 hours. Treatment course constitutes 10-15 daily procedures. ^ EFFECT: method ensures reduction of treatment and rehabilitation terms, normalisation of general state, as well as improvement of functional results due to increase of volume of movements in joints. ^ 1 ex, 7 dwg
A mining method for sample grouping is provided. The method includes the following steps. A field dataset including a plurality of samples is obtained, and each sample has a corresponding actual labeled result. The samples are respectively input to the existing model to obtain multiple estimation results. An outlier sample set in the field dataset is eliminated, and remaining samples in the field dataset form a remaining sample set based on difference distribution between the estimation results and the actual labeled results. The remaining sample set is grouped into a hard sample set and an easy sample set based on the estimation results of the remaining sample set.